晚发型狼疮肾炎死亡率更高但ESKD风险未增加
该拉丁美洲单中心回顾性队列比较晚发型(≥50岁)与早发型(18-49岁)系统性红斑狼疮(SLE)合并狼疮肾炎(LN)患者的肾脏生存与死亡结局。晚发型患者合并症更多、基线eGFR更低、慢性化评分略高,肾脏生存无显著差异,但全因死亡率更高、血肌酐倍增更常见、复合结局风险增加。
要点
- 晚发型LN肾脏生存与早发型无显著差异,但全因死亡率更高(48.3% vs 24.3%)。
- 晚发型LN复合结局风险增加(校正HR 1.58;95%CI 1.05-2.36)。
- 基线eGFR低、慢性化指数高、非肾脏损伤多与ESKD和死亡独立相关。
核心结论
- 晚发型SLE合并LN肾脏生存与早发型无显著差异,但合并症负担更重、慢性化评分略高、肾功能中间进展更差且死亡率更高。
- 研究支持将基线肾功能、组织学慢性化、合并症负担与竞争性死亡风险纳入风险分层。
研究设计与样本
- 单中心回顾性队列研究,纳入2011至2024年经活检证实的LN患者,按SLE发病年龄分为晚发型(≥50岁)与早发型(18-49岁)。
- 共纳入428例患者,其中370例(86.4%)为早发型,58例(13.6%)为晚发型;采用Cox比例风险模型及以死亡为竞争事件的竞争风险分析评估关联。
主要发现
- 晚发型SLE合并LN全因死亡率高于早发型(48.3% vs 24.3%,p < 0.001)。
- 晚发型血肌酐倍增更常见(18.5% vs 14.9%,p = 0.046)。
- 晚发型复合结局风险增加(校正HR 1.58;95%CI 1.05-2.36)。
- 两组肾脏生存无显著差异;晚发型合并症更多、基线eGFR更低、活检慢性化评分略高。
- 多变量分析中基线eGFR低、慢性化指数高、非肾脏损伤多与ESKD和死亡独立相关。
关键数值与推荐
- 晚发型定义为SLE发病年龄≥50岁,早发型为18-49岁。
- 全因死亡率48.3% vs 24.3%(p < 0.001);血肌酐倍增18.5% vs 14.9%(p = 0.046)。
- 复合结局校正HR 1.58;95%CI 1.05-2.36。
临床怎么用
- 对晚发型SLE合并LN患者应重视合并症负担与竞争性死亡风险,而不仅关注肾脏终点。
- 风险分层可整合基线eGFR、活检慢性化指数与非肾脏损伤程度。
局限性
- 为单中心回顾性队列研究,结论外推需谨慎。
- 晚发型样本量相对较小(58例),可能影响部分比较的效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare kidney survival, mortality, and composite outcomes in lupus nephritis (LN) according to age at systemic lupus erythematosus (SLE) onset (late-onset ≥50 years vs early-onset 18-49 years) in a Latin American cohort. METHODS: We conducted a single-center retrospective cohort study of patients with biopsy-proven LN diagnosed between 2011 and 2024 at a tertiary referral center. Outcomes included end-stage kidney disease (ESKD), all-cause mortality, doubling of serum creatinine, and a composite outcome (ESKD, creatinine doubling, or death). Associations between age at SLE onset and outcomes were evaluated using Cox proportional hazards models and competing-risk analysis for ESKD, with death as a competing event. RESULTS: Among 428 patients, 370 (86.4%) had early-onset SLE and 58 (13.6%) had late-onset SLE. Patients with late-onset SLE had more comorbidities, lower baseline eGFR, and slightly higher chronicity scores at biopsy. Kidney survival did not differ significantly between groups. However, late-onset SLE with LN was associated with higher all-cause mortality (48.3% vs 24.3%, p < 0.001), more frequent creatinine doubling (18.5% vs 14.9%, p = 0.046), and an increased risk of the composite outcome (adjusted HR 1.58; 95% CI 1.05-2.36). In multivariable analyses, lower baseline eGFR, higher chronicity index, and greater non-renal damage were independently associated with ESKD and mortality. CONCLUSIONS: Despite no significant difference in kidney survival, late-onset SLE with LN is characterized by higher comorbidity burden, slightly higher chronicity scores, worse intermediate renal decline, and higher mortality. These findings support integrating baseline kidney function, histological chronicity, comorbidity burden, and competing mortality risk into risk stratification.
引用
- Uribe-Ruíz NA, Vargas-Camacho AF, Aguirre-Hernández L, et al. Higher mortality without increased ESKD risk in late-onset SLE with lupus nephritis versus early-onset SLE: a Latin American cohort. Rheumatology (Oxford). 2026. PMID: 42568135. doi:10.1093/rheumatology/keag405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。